Illumina (NASDAQ:ILMN) Price Target Cut to $164.00
Illumina (NASDAQ:ILMN – Free Report) had its target price cut by Scotiabank from $176.00 to $164.00 in a research report report published on Thursday morning, Benzinga reports. They currently have a sector outperform rating on the life sciences company’s stock. Several other equities research analysts have also recently weighed in on ILMN. UBS Group increased […]
More Stories
Wall Street Zen Upgrades Health In Tech (NASDAQ:HIT) to Strong-Buy
Wall Street Zen upgraded shares of Health In Tech (NASDAQ:HIT – Free Report) from a buy rating to a strong-buy...
Mirum Pharmaceuticals (NASDAQ:MIRM) Raised to “Buy” at Wall Street Zen
Wall Street Zen upgraded shares of Mirum Pharmaceuticals (NASDAQ:MIRM – Free Report) from a hold rating to a buy rating...
Wall Street Zen Downgrades Fate Therapeutics (NASDAQ:FATE) to Sell
Wall Street Zen downgraded shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating...
QCR (NASDAQ:QCRH) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen cut shares of QCR (NASDAQ:QCRH – Free Report) from a hold rating to a sell rating in...
State of Alaska Department of Revenue Boosts Stake in Knife River Corporation (NYSE:KNF)
State of Alaska Department of Revenue increased its stake in shares of Knife River Corporation (NYSE:KNF – Free Report) by...
Donegal Group (NASDAQ:DGICA) Downgraded by Wall Street Zen to Buy
Wall Street Zen downgraded shares of Donegal Group (NASDAQ:DGICA – Free Report) from a strong-buy rating to a buy rating...